Funding Organization: National Institutes of Health (NIH)
Total Funding Amount: Up to $2,045,816 for Phase II awards
Duration: Up to 3 years
Objective: To assist SBCs in advancing products/technologies requiring Federal regulatory approval or bringing complex research tools to market.
This is a reissue of PAR-21-265, updated to align with agency priorities.
The program aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to commercialization.
Only U.S. small business concerns (SBCs) are eligible to apply.
SBCs must be organized for profit and primarily operate within the U.S.
SBCs must have not more than 500 employees.
Support for exploratory clinical trials or studies contributing to future trials.
Focus on medical biotechnology products, particularly for rare diseases and small patient populations.
Applications must aim to generate data that inform further clinical development.
Plans for future development must be outlined in case of promising results.
Applications must demonstrate readiness for FDA approval if applicable.
Studies should be designed to minimize bias and ensure validity.
Total funding support normally may not exceed $2,045,816 for Phase II awards.
Independent third-party funding equal to or greater than one-third of the NINDS funds requested is expected.
Earliest Submission Date: August 05, 2024
Application Due Dates: Various dates from September 05, 2024 to April 05, 2027.
IRB approval is required prior to funding.
Documentation of necessary regulatory approvals must be provided.
Applications must follow SBIR/STTR instructions in the How to Apply – Application Guide.
Documentation of third-party investor commitments is required.